Cardiovascular safety in the ustekinumab clinical development program: Final update with up to 5 years of follow-up

被引：0
|
作者：
Reich, Kristian [1 ]
Griffiths, C. E. M. [2 ]
Lebwohl, Mark [3 ]
Szapary, Philippe [4 ]
机构：
[1] Dermatologikum Hamburg, Hamburg, Germany
[2] Univ Manchester, Manchester, Lancs, England
[3] Mt Sinai Sch Med, New York, NY USA
[4] Janssen Res & Dev LLC, Spring House, PA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2013年 / 68卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：AB194 / AB194
页数：1
相关论文
共 50 条
  • [1] Cardiovascular safety in the ustekinumab Clinical Development Programme: final update with up to 5 years of follow-up
    Reich, K.
    Lebwohl, M.
    Griffiths, C. E. M.
    Szapary, P.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2013, 169 : 55 - 55
  • [2] Malignancies in the ustekinumab psoriasis clinical development program: Final report with up to 5 years of follow-up
    Papp, Kim
    Gordon, Kenneth
    Szapary, Philippe
    Ho, Vincent
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (04) : AB206 - AB206
  • [3] Infections in the ustekinumab psoriasis clinical trial program: Final report with up to 5 years of follow-up
    Strober, Bruce
    Lebwohl, Mark
    Ghislain, P. D.
    Szapary, Philippe
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (04) : AB203 - AB203
  • [4] Malignancies in the ustekinumab psoriasis clinical development programme: final report with up to 5 years of follow-up
    Papp, K.
    Gordon, K.
    Ho, V.
    Szapary, P.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2013, 169 : 40 - 40
  • [5] An Update on the Long-Term Safety Experience of Ustekinumab: Results From the Psoriasis Clinical Development Program With up to Four Years of Follow-Up
    Reich, Kristian
    Papp, Kim A.
    Griffiths, Christopher E. M.
    Szapary, Philippe O.
    Yeilding, Newman
    Wasfi, Yasmine
    Ott, Elyssa
    Hsu, Ming-Chun
    Lebwohl, Mark
    Gordon, Kenneth B.
    [J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2012, 11 (03) : 300 - 312
  • [6] Update on cardiovascular safety of Ustekinumab in pooled phase 2 and 3 psoriasis clinical trials with up to 4 years of follow-up
    Reich, K.
    Langley, R. G.
    Lebwohl, M.
    Szapary, P. O.
    Yeilding, N.
    Hsu, M. C.
    Griffiths, C. E. M.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2012, 53 : 51 - 52
  • [7] Update on the cardiovascular safety of ustekinumab in pooled phase II and III psoriasis clinical trials with up to 4 years of follow-up
    Reich, K.
    Griffiths, C. E. M.
    Lebwohl, M.
    Szapary, P. O.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB206 - AB206
  • [8] Infection rates in the ustekinumab psoriasis clinical trial program: Update with up to 4 years of follow-up
    Kimball, A. B.
    Menter, A.
    Reich, K.
    Szapary, P. O.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB195 - AB195
  • [9] Infection rates in the Ustekinumab psoriasis clinical trial program: Update with up to 4 years of follow-up
    Kimball, A. B.
    Bissonnette, R.
    Leonardi, C.
    Menter, A.
    Szapary, P. O.
    Wasfi, Y.
    Ott, E.
    Hsu, M.
    van de Kerkhof, P.
    Reich, K.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2012, 53 : 52 - 52
  • [10] Infections in the ustekinumab psoriasis clinical trial programme: final report with up to 5 years of follow-up
    Strober, B.
    Ghislain, P. D.
    Lebwohl, M.
    Szapary, P.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2013, 169 : 38 - 38
12345